Zosano inks $32.5M development deal; FDA approves COPD treatment;

 

 @FierceBiotech: Mobile tech veteran Chris Toumazou pioneers DNA analysis methods. Article | Follow @FierceBiotech

 @ JohnCFierce: Third Rock seeds a new approach to treating diabetes and obesity. Item | Follow @JohnCFierce

 @RyanMFierce: Do niche EDC players stand a chance? This Dublin upstart has found its sweet spot with EDC for post-market apps Report | Follow @RyanMFierce

 @MaureenFierce: CA passes law that removes parental consent for vaccinating kids 12 and older against STDs. More | Follow @MaureenFierce

 

> Fremont, CA-based Zosano Pharma has inked an Asian marketing pact with Asahi Kasei Pharma for the development of a weekly transdermal patch formulation of Teribone (teriparatide acetate), AKP's formulation of human parathyroid hormone for the treatment of osteoporosis patients. The patch product uses Zosano's microprojection technology. Zosano gets $7.5 million upfront with a promise of $25 million in milestones. Release

> The FDA has approved Combivent respimat for COPD. The treatment uses a mist formulation of Combivent Inhalation Aerosol. Story

> Mass High Tech reports that Courtagen Life Sciences has raised $8 million from a roster of 67 investors. Article

> Dynavax Technologies ($DVAX) announced Phase III immunogenicity data for hypo-responsive subpopulations--namely males, the obese, and smokers--for its hepatitis B vaccine, Heplisav. Release

Pharma News

 @FiercePharma: From NYT, a Q&A with Novartis chief Joe Jimenez, including how he learned to welcome bad news Story | Follow @FiercePharma

> Teva sells rights to gain FTC nod for Cephlon deal. News

> Want to impress Novartis' CEO? Don't do it in PowerPoint. Item

> Novo chief can stand the heat on drug bargaining. Story

> J&J's Zytiga's pain relief, ease of use beat Provenge. Article

> AstraZeneca earmarks $200M for Chinese plant. Article

> Pfizer, Teva settle rancorous Lipitor fight in U.K. Report

 

Medical Device News

> MAKO aims to get hip-replacement patients back on feet faster. Piece

> Axis-Shield accepts increased Alere offer. Report

> FDA, CMS launch parallel review pilot. Item

> AngioDynamics sees net income fall in Q1. Article

> Ex-Medtronic CEO Hawkins to head Immucor. Report

Biotech IT News

> Mobile tech vet pioneers DNA analysis methods. Story

> Honoring bioinformatics pioneer on Ada Lovelace Day. More

> EDC upstart CTEP tackles Ph4 market. Article

> Software models response to H. pylori. Item

> Eric Schadt leading biotech computing charge in NYC. More

> Kansas U. nails bioinformatics faculty members for part in plagiarism. News

 

And Finally... A new Gallup polls shows that there are just a few more Americans who rate as normal weight than obese, which indicates a positive trend line in the battle against the bulge. Story

Suggested Articles

Biogen will develop a gene therapy with the goal of preserving and possibly restoring vision in patients with PRPF31-mutated retinitis pigmentosa.

A month after moving its COVID-19 antibody cocktail into human trials, Regeneron is testing the drug's ability to ward off COVID-19 infection.

Short reports are nothing new, but the aggressive “I’m coming after you” PR from Applied Therapeutics certainly is.